Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial – marketscreener.com

Salarius Pharmaceuticals Achieves Dosing Milestone in Ongoing Phase 1/2 Sarcoma Trial – marketscreener.com

Sales 2021 2,15 M

Net income 2021 -12,8 M

Net Debt 2021

P/E ratio 2021 -1,75x
Yield 2021
Capitalization 23,7 M
23,7 M
Capi. / Sales 2021 11,1x
Capi. / Sales 2022 19,0x
Nbr of Employees 8
Free-Float 98,5%

Chart SALARIUS PHARMACEUTICALS, INC.

Duration : Auto.2 months3 months6 months9 months1 year2 years5 years10 yearsMax.


Period : DayWeek

<td id="btn_3C_Line_o" onclick="myChange3charts.Exec('sBaseLink=&iCodeZB=62465383&iGrafHeight=360&iGrafWidth=336&bGrafNews=0&bNoAT=&sRightLink=&bOuterPadding=1&bLienSuite=1&sCycle=DAY&iDuration=0&…….

Source: https://www.marketscreener.com/quote/stock/SALARIUS-PHARMACEUTICALS-62465383/news/Salarius-Pharmaceuticals-Achieves-Dosing-Milestone-in-Ongoing-Phase-1-2-Sarcoma-Trial-37436147/

Alternative medicines

Leave a Reply

Your email address will not be published. Required fields are marked *